CIK 0000014272 · Large accelerated filer
BRISTOL MYERS SQUIBB CO
Sign in to watch- Ticker
- BMY
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 220790350
- Phone
- 6092524621
- Business address
- ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NJ, 08543
Securities
- BMY Bristol-Myers Squibb Company Common Stock NYSE
- CELG-RI Rights NYSE
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $677,826
- in 3 filings
Net −$677,826. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-03 | Short Bartie Wendy EVP, Corporate Affairs | Option exercise | +8,040 | 15,957 | ||
| 2026-06-03 | Short Bartie Wendy EVP, Corporate Affairs | Shares withheld for taxes | −3,876 | $54.72 | $212K | 12,081 |
| 2026-06-03 | Short Bartie Wendy EVP, Corporate Affairs | Option exercise · Restricted Stock Units | −8,040 | 8,040 | ||
| 2026-05-01 | Lenkowsky Adam EVP, Chief Commercial Officer | Option exercise | +1,373 | 20,508 | ||
| 2026-05-01 | Lenkowsky Adam EVP, Chief Commercial Officer | Other disposition | −203 | 20,305 | ||
| 2026-05-01 | Lenkowsky Adam EVP, Chief Commercial Officer | Shares withheld for taxes | −599 | $58.22 | $35K | 19,706 |
| 2026-05-01 | Lenkowsky Adam EVP, Chief Commercial Officer | Option exercise · Market Share Units | −1,373 | 1,375 | ||
| 2026-04-01 | Shanahan Karin EVP, Chief Supply Chain & Ops | Option exercise | +3,307 | 27,580 | ||
| 2026-04-01 | Shanahan Karin EVP, Chief Supply Chain & Ops | Shares withheld for taxes | −1,692 | $61.73 | $104K | 25,888 |
| 2026-04-01 | Shanahan Karin EVP, Chief Supply Chain & Ops | Option exercise · Restricted Stock Units | −3,307 | 0 | ||
| 2026-04-01 | Elkins David V EVP, Chief Financial Officer | Sale | −25,519 | $61.60 | $1.6M | 163,729 |
| 2026-04-01 | Elkins David V EVP, Chief Financial Officer | Sale | −4,481 | $62.05 | $278K | 159,248 |
| 2026-03-31 | Samuels Theodore R. II Director | Grant or award · Deferred Share Units | +845.01 | $60.65 | $51K | 68,727.52 |
| 2026-03-31 | McMullen Michael R. Director | Grant or award · Deferred Share Units | +577.08 | $60.65 | $35K | 15,556.77 |
| 2026-03-31 | Rice Derica W Director | Grant or award · Deferred Share Units | +638.91 | $60.65 | $39K | 39,963.72 |
| 2026-03-31 | Arduini Peter J Director | Grant or award · Deferred Share Units | +577.08 | $60.65 | $35K | 71,435.17 |
| 2026-03-31 | YALE PHYLLIS R Director | Grant or award · Deferred Share Units | +577.08 | $60.65 | $35K | 43,903.78 |
| 2026-03-10 | Massacesi Cristian EVP,Chief Med Offr,Head of Dev | Grant or award · Market Share Units | +26,122 | 26,122 | ||
| 2026-03-10 | Massacesi Cristian EVP,Chief Med Offr,Head of Dev | Grant or award · Performance Shares | +39,184 | 39,184 | ||
| 2026-03-10 | Shibutani Hiroshi Chris EVP, Chief Strategy Officer | Grant or award · Market Share Units | +7,837 | 7,837 |
Page 3 of 40 · 799 trades